Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Aristotle University Of Thessaloniki
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06523530CT.gov Effect of a GnRH Analog on Hepatic Steatosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometriosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Goserelin (this asset) | Aristotle University Of Thessaloniki | Approved | BB · 65 |
| Continuous Microgestin 1/20 | Endeavor Health | P4 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | University Hospitals Cleveland Medical Center | P4 | BB |
| Rocuronium Ion | Stony Brook University | P4 | BB |
| Cyclic Microgestin 1/20 | Endeavor Health | P4 | BB |
| Ulipristal Acetate | Northwestern University | P4 | BB |
| Danazol | Centre for Endocrinology and Reproductive Medicine, Italy | P4 | BB |
| Xuefu-Zhuyu | Zhong Wang | P4 | BB |
| Chlormadinone Acetate | University Magna Graecia | P4 | BB |
+21 more in the Endometriosis cohort
Other indications for Goserelin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 70 |
| Prostate Carcinoma | — | P3 | BB · 69 |
| Prostate Adenocarcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Goserelin in Endometriosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/goserelin-endometriosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →